PPARα activation is known to improve steatosis and inflammation in pre-clinical models of NAFLD, whereas mice lacking hepatocytic PPARα develop hepatic steatosis and patients with NAFLD display reduced expression of PPARα23,36. This evidence concerns the gene PPARA and Hepatic steatosis.